Vrdoljak Eduard, Boban Marijo, Saratlija-Novaković Zana, Jović Josipa
Center of Oncology, Split University Hosipital, Split, Croatia.
Croat Med J. 2006 Apr;47(2):305-9.
We describe the response to a new chemotherapy agent, topoisomerase I inhibitor edotecarin in an 18-year-old woman with recurring glioblastoma. The therapy was administered for 17 months. The radiological partial response and clinical improvement have been achieved, with minor toxicity. Median survival of patients with glioblastoma is 10 months. With edotecarin we have achieved promising result, which should encourage further investigations to develop more efficient therapy for such a deadly disease.
我们描述了一名18岁复发性胶质母细胞瘤女性患者对新型化疗药物拓扑异构酶I抑制剂依多卡林的反应。该治疗持续了17个月。已实现影像学部分缓解和临床改善，且毒性较小。胶质母细胞瘤患者的中位生存期为10个月。使用依多卡林我们取得了有前景的结果，这应鼓励进一步开展研究，以开发针对这种致命疾病更有效的治疗方法。
